Trial reportJournal of cardiovascular electrophysiology2025
Superwide Left Atrial Circumferential Ablation for Persistent Atrial Fibrillation: A Randomized Controlled Trial.
Trial report in Journal of cardiovascular electrophysiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Wide-Antral pulmonary vein isolation in patients undergoing atrial fibrillation ablation with a Single-Shot technique: rationale and design of the WIDER-PVI trial.Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing · 2026Trial
- A topological hypothesis for atrial fibrilllation, atrial flutter and focal atrial tachycardia: comparison and contrast with Kosterlitz-Thouless physics.Frontiers in network physiology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundIt remains to be answered whether further enlargement of the isolation area in the left atrium (LA) could produce better effectiveness than pulmonary vein antrum isolation (PVAI) for treatment of atrial fibrillation (AF).
aimsTo assess the effectiveness of superwide left atrial circumferential ablation (SWLACA) for treatment of persistent AF (PeAF) through a randomized controlled study.
methodsA total of 248 patients (male 63.7%, median age 65 years) with PeAF were randomly divided into the SWLACA group and PVAI group. The circumferential lines were located 2-3 cm from the PV ostia in the SWLACA group and approximately 1 cm in the PVAI group, respectively. The primary endpoint was the recurrence of atrial tachyarrhythmia after a single procedure.
resultsConduction block between LA and pulmonary veins (PVs) were achieved in all patients. The isolation areas were obviously larger in the SWLACA group (p < 0.001). Compared with the PVAI group, the SWLACA group was associated with a longer procedure duration (p = 0.013) and fluoroscopic time (p = 0.038). During the 12-month follow-up, the overall recurrence rate of atrial tachyarrhythmia after a single procedure was not significantly different between the two groups (21.0% vs 26.6%; p = 0.297). However, the SWLACA group had significantly fewer AF recurrences (12.9% vs. 25.0%; p = 0.015), and more atrial tachycardia recurrences (8.1% vs. 1.6%; p = 0.018). After multiple procedures, the SWLACA group had a significantly higher total arrhythmia recurrence-free rate (p = 0.030).
conclusionsCompared with PVAI, although SWLACA did not significantly decrease the overall arrhythmia recurrence rate for PeAF, it was associated with a notable reduction in the recurrence of AF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.